Effects of microinjections of cholecystokinin and neurotensin into lateral hypothalamus and ventral mesencephalon on intracranial self-stimulation

The unappreciated roles of the cholecystokinin receptor CCK(1) in brain functioning

The CCK(1) receptor is a G-protein-coupled receptor activated by the sulfated forms of cholecystokinin (CCK), a gastrin-like peptide released in the gastrointestinal tract and mammal brain. A substantial body of research supports the hypothesis that CCK(1)r stimulates gallbladder contraction and pancreatic secretion in the gut, as well as satiety in brain. However, this receptor may also fulfill relevant roles in behavior, thanks to its widespread distribution in the brain. The strategic location of CCK(1)r in mesolimbic structures and specific hypothalamic and brainstem nuclei lead to complex interactions with neurotransmitters like dopamine, serotonin, and glutamate, as well as hypothalamic hormones and neuropeptides. The activity of CCK(1)r maintains adequate levels of dopamine and regulates the activity of serotonin neurons of raphe nuclei, which makes CCK(1)r an interesting therapeutic target for the development of adjuvant treatments for schizophrenia, drug addiction, and mood disorders. Unexplored functions of CCK(1)r, like the transmission of interoceptive sensitivity in addition to the regulation of hypothalamic hormones and neurotransmitters affecting emotional states, well-being, and attachment behaviors, may open exciting roads of research. The absence of specific ligands for the CCK(1) receptor has complicated the study of its distribution in brain so that research about its impact on behavior has been published sporadically over the last 30 years. The present review reunites all this body of evidence in a comprehensive way to summarize our knowledge about the actual role of CCK in the neurobiology of mental illness.

To ingest or rest? Specialized roles of lateral hypothalamic area neurons in coordinating energy balance

Survival depends on an organism’s ability to sense nutrient status and accordingly regulate intake and energy expenditure behaviors. Uncoupling of energy sensing and behavior, however, underlies energy balance disorders such as anorexia or obesity. The hypothalamus regulates energy balance, and in particular the lateral hypothalamic area (LHA) is poised to coordinate peripheral cues of energy status and behaviors that impact weight, such as drinking, locomotor behavior, arousal/sleep and autonomic output. There are several populations of LHA neurons that are defined by their neuropeptide content and contribute to energy balance. LHA neurons that express the neuropeptides melanin-concentrating hormone (MCH) or orexins/hypocretins (OX) are best characterized and these neurons play important roles in regulating ingestion, arousal, locomotor behavior and autonomic function via distinct neuronal circuits. Recently, another population of LHA neurons containing the neuropeptide Neurotensin (Nts) has been implicated in coordinating anorectic stimuli and behavior to regulate hydration and energy balance. Understanding the specific roles of MCH, OX and Nts neurons in harmonizing energy sensing and behavior thus has the potential to inform pharmacological strategies to modify behaviors and treat energy balance disorders.

The role of neurotensin in positive reinforcement in the rat central nucleus of amygdala

In the central nervous system neurotensin (NT) acts as a neurotransmitter and neuromodulator. It was shown that NT has positive reinforcing effects after its direct microinjection into the ventral tegmental area. The central nucleus of amygdala (CeA), part of the limbic system, plays an important role in learning, memory, regulation of feeding, anxiety and emotional behavior. By means of immunohistochemical and radioimmune methods it was shown that the amygdaloid body is relatively rich in NT immunoreactive elements and NT receptors. The aim of our study was to examine the possible effects of NT on reinforcement and anxiety in the CeA. In conditioned place preference test male Wistar rats were microinjected bilaterally with 100 or 250 ng NT in volume of 0.4 microl or 35 ng neurotensin receptor 1 (NTS1) antagonist SR 48692 alone, or NTS1 antagonist 15 min before 100 ng NT treatment. Hundred or 250 ng NT significantly increased the time rats spent in the treatment quadrant. Prior treatment with the non-peptide NTS1 antagonist blocked the effects of NT. Antagonist itself did not influence the reinforcing effect. In elevated plus maze test we did not find differences among the groups as far as the anxiety index (time spent on the open arms) was concerned. Our results suggest that in the rat ACE NT has positive reinforcing effects. We clarified that NTS1s are involved in this action. It was also shown that NT does not influence anxiety behavior.

Neurotensin: role in psychiatric and neurological diseases

Neurotensin (NT), an endogenous brain-gut peptide, has a close anatomical and functional relationship with the mesocorticolimbic and neostriatal dopamine system. Dysregulation of NT neurotransmission in this system has been hypothesized to be involved in the pathogenesis of schizophrenia. Additionally, NT containing circuits have been demonstrated to mediate some of the mechanisms of action of antipsychotic drugs, as well as the rewarding and/or sensitizing properties of drugs of abuse. NT receptors have been suggested to be novel targets for the treatment of psychoses or drug addiction.

Mapping the Neural Substrate Underlying Brain Stimulation Reward with the Behavioral Adaptation of Double-Pulse Methods

Behavioral adaptations of double-pulse methods--primarily collision and refractory period tests--have been employed to unveil the electrophysiological and anatomical characteristics of neural networks of known function. These paradigms are based on trade-off functions: a determination of different combinations of stimuli that yield the same behavioral output. A detailed explanation of the logic and methodology underlying these techniques is elaborated in this paper. The implementation of such approaches to the study of brain stimulation reward (BSR) has provided a means of discriminating between the neurons underlying this behavior from other cells activated by the stimulating electrode, endowing them with a particularly powerful scientific scope. An increasingly detailed portrait of the BSR substrate, both within and outside the medial forebrain bundle, has been emerging as a result of these investigations and is reviewed in this paper. Finally, the challenges associated with these paradigms are discussed and potential solutions as well as future experimental ventures proposed. Attention is drawn to the major contribution of these methods to our understanding of the neural pathways and characteristics underlying BSR.

Central D-Ala2-Met5-enkephalinamide mu/delta-opioid receptor activation blocks behavioral sensitization to cholecystokinin in CD-1 mice

The present investigation revealed that intraventricular administration of the anxiogenic substance CCK-8S (50 ng) decreased responding for previously rewarding brain stimulation (intracranial self-stimulation; ICSS) and subsequently increased brain stimulation threshold determinations from the dorsal aspects of the ventral tegmental area (VTA) immediately following CCK administration. While central administration of the mixed mu/delta opioid receptor agonist D-Ala(2)-Met(5)-enkephalinamide (DALA; 1 microg) was ineffective in abrogating CCK induced ICSS deficits during the immediate post-stressor interval, DALA restored ICSS brain stimulation thresholds to basal values 24, 48 and 168 h following CCK challenge. At 18 days following the initial 50 ng CCK-8S and/or DALA challenges, mice were exposed to a previously determined non-anxiogenic dose of CCK-8S (5 ng). Among mice which received an intervening dose of saline following the 50 ng CCK-8S challenge, depressed ICSS responding and elevated brain stimulation thresholds were evident during the immediate (Day 18), 24- (Day 19) and 48-h (Day 20) test sessions relative to mice that received an intervening dose of DALA on Day 1. These data imply that while CCK induces relatively protracted and exaggerated behavioral disturbances, mu/delta opioid-receptor activation may block CCK-induced behavioral sensitization and change the course of psychopathology.

Neurotensin regulates intracellular calcium in ventral tegmental area astrocytes: evidence for the involvement of multiple receptors

Recent evidence suggests that some types of neurotensin receptors may be expressed by astrocytes. In order to explore the function of neurotensin receptors in astrocytes, the effect of a neurotensin receptor agonist, neurotensin(8-13), on intracellular Ca(2+) dynamics in mixed neuronal/glial cultures prepared from rat ventral tegmental area was examined. It was found that neurotensin(8-13) induces a long-lasting rise in intracellular Ca(2+) concentration in a subset of glial fibrilary acidic protein-positive glial cells. This response displays extensive desensitization and appears to implicate both intracellular and extracellular Ca(2+) sources. In the absence of extracellular Ca(2+), neurotensin(8-13) evokes only a short-lasting rise in intracellular Ca(2+). The neurotensin-evoked intracellular Ca(2+) accumulation is blocked by the phospholipase C inhibitor U73122 and by thapsigargin, suggesting that it is initiated by release of Ca(2+) from an inositol triphosphate-dependent store. The Ca(2+)-mobilizing action of neurotensin(8-13) in astrocytes is dependent on at least two receptors, because the response is blocked in part only by SR48692, a type 1 neurotensin receptor antagonist, and is blocked completely by SR142948A, a novel neurotensin receptor antagonist. The finding that the type 2 neurotensin receptor agonist levocabastine fails to mimic or alter the effects of neurotensin(8-13) on intracellular Ca(2+) makes it unlikely that the type 2 neurotensin receptor is involved. In summary, these results show that functional neurotensin receptors are present in cultured ventral tegmental area astrocytes and that their activation induces a highly desensitizing rise in intracellular Ca(2+). The pharmacological profile of this response suggests that a type 1 neurotensin receptor is involved but that another, possibly novel, non-type 2 neurotensin receptor is also implicated. If present in vivo, such signalling could be involved in some of the physiological actions of neurotensin.

The effects of cholecystokinin on stimulation-induced feeding and self-stimulation

Cholecystokinin (CCK) is a peptide hormone which controls a number of important functions during the process of digestion. It is present in the gut and the central nervous system, although its exact role in the latter is not yet clear. Our interest was in the effects of intraperitoneal and intracerebral injections of CCK on brain stimulation reward and stimulation-induced feeding. Period thresholds for rewarding stimulation were unaffected by either route of peptide administration, whereas stimulation-induced feeding thresholds were weakly increased by centrally injected CCK. In addition, we evaluated stimulation-induced feeding using a more resolved measure and found it to provide clearer results. By actually measuring the amount of food eaten during a stimulation-induced feeding session, and not only the occurrence of feeding, CCK was shown to systematically decrease the total intake as a function of dose in an inverse manner. The efficiency of food utilization was calculated for each animal during the different phases of the experiment in order to monitor the effects of CCK on the animals' overall health. Centrally administered CCK appeared to increase the animals' efficiency and, furthermore, this level was sustained for the entire post-injection phase, about 2 weeks, suggesting a relatively enduring increase in metabolic rate. While the functional role of central CCK and other gastric peptides requires clarification, analyses which exploit the stimulation-induced feeding paradigm need to make use of more clearly defined microstructural variables.